4.2 Article

Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019

期刊

INTERNAL MEDICINE
卷 59, 期 18, 页码 2327-2329

出版社

JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.5377-20

关键词

acute gouty arthritis; coronavirus disease 2019 (COVID-19); favipiravir; hyperuricemia; severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)

向作者/读者索取更多资源

A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据